Calliditas Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Stockholm Sweden (2004)

Organization Overview

First Clinical Trial
2004
NCT00160082
First Marketed Drug
2021
budesonide (rhinocort)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CALLIDITAS | Calliditas Therapeutics AB | Calliditas Therapeutics Suisse SA | Pharmalink | Pharmalink AB | Pharmalink AB, Stockholm, Sweden | Pharmalink International Ltd.

Active Ingredients

Marketed Drugs (1)

budesonide (rhinocort) (2021)

Drugs in Phase 3 Trials (2)

Key: Calliditas Therapeutics (1) Acquired (1)

budesonide (rhinocort) (4 trials)

setanaxib (3 trials)

Drugs in Phase 2 Trials (3)

Key: Calliditas Therapeutics (1) Acquired (2)

gkt137831 (3 trials)

pembrolizumab (keytruda) (1 trial)

procervix (1 trial)

Drugs in Phase 1 Trials (3)

Key: Calliditas Therapeutics (1) Acquired (2)

greenshell mussel extract (1 trial)

gtl001 (1 trial)

imiquimod (aldara) (1 trial)

Drugs in Other Trials (2)

fish oil (Omegavan) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glomerulonephritis, IGA (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 10